Abstract: There is provided an imaging agent for use in a method of visualization of HER2 expression in a human patient, said method comprising administering the imaging agent to the patient in a dose of 400-700 ?g and subsequently a scanning of the patient to visualize HER2 expression, wherein the imaging agent is a conjugate comprising a radionuclide and a HER2-binding protein (HBP) of a certain amino acid sequence. Further there is provided a unit dose comprising the imaging agent in an amount of 400-700 ?g.

Abstract: A pharmaceutical composition intended for the treatment of an acute leukemia which comprises, as the active principle, N,N.sup.3 -di-(.beta.-bromopropionyl)-N.sup.1,N.sup.2 -dispirotripiperazinium dichloride and a pharmaceutically acceptable vehicle therefor. The active principle is used as a lyophilized powder. As the vehicle use is made of an isotonic solution of sodium chloride or distilled water. The content of the active principle in the pharmaceutical composition for injections is 2 to 5% by weight.

Abstract: 2-Dimethylamino-6-diethylenimidophosphamido-7-methylpurine having the formula ##STR1## A method for preparing 2-dimethylamino-6-diethylenimido-phosphamido-7-methylpurine consisting of treating theobromine with heating to the boiling point and subsequently with phosphorus oxychloride and phosphorus pentachloride. The prepared 2,6-dichloro-7-methylpurine is heated to 50.degree.-60.degree. C. in an aqueous solution of ammonia and the resulting 2-chloro-6-amino-7-methylpurine is reacted, with heating, with an aqueous solution of dimethylamine. The obtained 2-dimethylamino-6-amino-7-methylpurine is reacted, at the boiling point, with either phosphorus oxychloride, or phosphorus pentachloride and formic acid. The resulting 2-dimethylamino-7-methylpurinyl-6-aminophosphoric dichloroanhydride is then treated with ethylenemine in a medium of an organic solvent in the presence of an acceptor of hydrogen chloride, and the final product is then isolated.